Gene therapy of prostate cancer: p53, suicidal genes, and other targets

Anticancer Research

Volumn 17, Issue 3 A, 1997, Pages 1471-1505

  Boulikas, Teni ^a  

^a Inst of Molecular Medical Sciences   (United States)

Author keywords

Androgen receptor; Apoptosis; Bax; Bcl 2; Cationic liposomes; Chromatin; DNA repair; Gene therapy; HSV tk; p21; p53; Prostate cancer; Stealth liposomes; Steroid hormones

Indexed keywords

ANDROGEN RECEPTOR; ANTIANDROGEN; BICALUTAMIDE; CHLOROTRIANISENE; CYPROTERONE; DIETHYLSTILBESTROL; ESTRAMUSTINE; ETHINYLESTRADIOL; GONADORELIN; GOSERELIN; LEUPRORELIN; LIPOSOME; NILUTAMIDE; POLYESTRADIOL PHOSPHATE; PROSTATE SPECIFIC ANTIGEN; PROTEIN P53; SOMATOMEDIN;

ADENOVIRUS; ALLELE; ANIMAL CELL; APOPTOSIS; ARTICLE; CANCER HORMONE THERAPY; CANCER THERAPY; CARCINOGENESIS; CELL CULTURE; CELL CYCLE; CELL PROLIFERATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DNA REPAIR; DRUG RECEPTOR BINDING; DRUG STRUCTURE; GENE MUTATION; GENE TARGETING; GENE THERAPY; GENE TRANSFER; HUMAN; HUMAN CELL; MALE; META ANALYSIS; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; PROMOTER REGION; PROSTATE CANCER; RECEPTOR UPREGULATION; RETROVIRUS; SIGNAL TRANSDUCTION; SUICIDE GENE; TUMOR SUPPRESSOR GENE;

ANDROGENS; APOPTOSIS; CELL CYCLE; FEMALE; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENES, P53; GENETIC VECTORS; HUMANS; MALE; MODELS, BIOLOGICAL; PROSTATIC NEOPLASMS; RETROVIRIDAE; SIGNAL TRANSDUCTION;

EID: 0030920998     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (237)

1. Schneider C, Gustincich S, and Del Sal G: The complexity of cell proliferation control in mammalian cells. Curr Opin Cell Biol 3: 276-281, 1991.
2. Ames BN: Identifying environmental chemicals causing mutations and cancer, Science 204: 587-593, 1979.
3. Boulikas T: DNA lesion-recognizing proteins and the p53 connection. Anticancer Res 16: 225-242, 1996.
4. Boulikas T: Xeroderma pigmentosum and molecular cloning of DNA repair genes. Anticancer Res 16: 693-708, 1996.
5. Varmus HE.: The molecular genetics of cellular oncogenes. Ann Rev Genet 18: 553-612, 1984.
6. Bishop JM: Molecular themes in oncogenesis. Cell 64: 235-248, 1991.
7. Vogelstein B and Kinzler K: p53 function and dysfunction. Cell 70: 523-526, 1992.
8. Anders F, Schartl M, Barnekow A, and Anders A: Xiphophorus as an in vivo model for studies on normal and defective control of oncogenes. Adv Cancer Res 42: 191-275, 1984.
9. Leach FS, Nicolaides NC, Papadopoulos N, Liu B, Jen J, Parsons R, Peltomaki P, Sistonen P, Aaltonen A, Nystom-Lahti M, Guan X- Y, Zhang J, Meltzer PS, Yu J-W, Kao F-T, Chen DJ, Cerosaletti KM, Fournier REK, Todd S, Lewis T, Leach RJ, Naylor SL, Weissenbach J, Mecklin J-P, Jarvinen H, Petersen GM, Hamilton SR, Green J, Jass J, Watson P, Lynch HT, Trent JM, de la Chepelle A, Kinzler KW, and Vogelstein B: Mutations of a mutS homolog in hereditary nonpolyposis colorectal cancer. Cell 75: 1215-1225, 1993.
10. Chen Y, Chen C-F, Riley DJ, Allred DC, Chen P-L, Von Hoff D, Osborne CK, and Lee W-H: Aberrant subcellular localization of BRCAl in breast cancer. Science 270: 789-791, 1995.
11. Boulikas T: The phosphorylation connection to cancer. Int J Oncol 6: 271-278, 1995.
12. Boulikas T: Phosphorylation of transcription factors and the control of the cell cycle. Crit Rev Eukar. Gene Expression 5: 1-77, 1995.
13. Weijerman PC, König JJ, Wong ST, Niesters HGM, and Peehl DM: Lipofection-mediated immortalization of human prostatic epithelial cells of normal and malignant origin using human papillomavirus type 18 DNA. Cancer Res 54: 5579-5583, 1994.
14. Labrie F, Bélanger A, Dupont A, Luu-The V, Simard J, and Labrie C: Science behind total androgen blockade: from gene to combination therapy. Clin Invest Med 76: 475-492, 1993.
15. Martel C, Trudel C, Couet J, Labrie C, Bélanger A, and Labrie F: Blockade of androstenedione-induced stimulation of androgen-sensitive parameters in the rat prostate by combination of flutamide and 4-MA. Mol Cell Endocrinol 91: 43-49, 1993.
16. Cox RL and Crawford ED: Review article: estrogens in the, treatment of prostate cancer. J Urol 154: 1991-1998, 1995.
17. Carter BS, Ewing CM, Ward WS, Treiger BF, Aalders TW, Schalken JA, Epstein JI, and Isaacs WB: Allelic loss of chromosomes 16q and 10q in human prostate cancer. Proc Natl Acad Sci USA 87: 8751-8755, 1990.
18. Pang S, Taneja S, Dardashti K, Cohan P, Kaboo R, Sokoloff M, Tso C-L, Dekernion JB, and Belldegrun AS: Prostate tissue specificity of the prostate-specific antigen promoter isolated from a patient with prostate cancer. Hum Gene There 6: 1417-1426, 1995.
19. Koutsilieris M: Skeletal metastases in advanced prostate cancer: cell biology and therapy. Crit Rev Oncol/Hematol 18: 51-64, 1995.
20. Sandberg AA and Turc-Carel C: The cytogenetics of solid tumors. Cancer 59: 387-395, 1987.
21. Carter RL: Patterns and mechanisms of bone metastases. J. Royal Soc Med Suppl 78: 2-6, 1985
22. Athanasou NA: Tumour infiltrating macrophages and metastasis- associated osteolysis (Review). Int J Oncol 2: 261-263, 1993.
23. Koutsilieris M, Frenette G, Lazure C, Lehoux JG, Govindan MV, Polychronakos C: Urokinase-type plasminogen activator: a paracrine factor regulating the bioavailability of IGFs in PA-III cell-induced osteoblastic metastases. Anticancer Res 13: 481-486, 1993.
24. Ichikawa T, Ichikawa Y, Dong J, Hawkins AL, Griffith CA, Isaacs WB, Oshimura M, Barrett JC, and Isaacs JT: Localization of metastasis suppressor gene(s) for prostatic cancer to the short arm of human chromosome 11. Cancer Res 52: 3486-3490, 1992.
25. Ichikawa T, Nihei N, Suzuki H, Oshimura M, Emi M, Nakamura Y, Hayata I, Isaaks JT, and Shimazaki J: Suppression of metastasis of rat prostate cancer by introducing human chromosome 8. Cancer Res 54: 2299-2302, 1994.
26. Bérubé NG, Speevak MD, and Chevrette M: Suppression of tumorigenicity of human prostate cancer cells by introduction of human chromosome del(12)(q13). Cancer Res 54: 3077-3081, 1994.
27. Leone A, Flatow U, King CR, Sandeen MA, Margulies IMK, Liotta LA, and Steeg PS: Reduced tumor incidence, metastatic potential, and cytokine responsive of nm23 transfected melanoma cells. Cell 65: 25-31, 1991.
28. Bookstein R, Shew J-Y, Chen P-L, Scully P, and Lee W-H: Suppression of tumorigenicity of human prostate carcinoma cells by replacing a mutated RB gene. Science 247: 712-715, 1990.
29. Boulikas T: Nuclear localization signals (NLS). Crit Rev Eukar Gene Expression 3: 193-227, 1993.
30. Crawford D, Eisenberger MA, McLeod DG, Spaulding JT, Benson R, Dorr FA, Blumenstein BA, Davis MA, and Goodman PI: A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med 313: 419-424, 1989.
31. Dai Y, Schwarz EM, Gu D, Zhang W-W, Sarvetnick N, and Verma IM: Cellular and humoral immune responses to adenoviral vectors containing factor IX gene: tolerization of factor IX and vector antigens allows for long-term expression. Proc Natl Acad Sci USA 92: 1401-1405, 1995.
32. Cao L, Zheng Z-C, Zhao Y-C, Jiang Z-H, Liu Z-G, Chen S-D, Zhou C-F, and Liu X-Y (1995) Gene therapy of Parkinson disease model rat by direct injection of plasmid DNA-lipofectin complex. Hum Gene Ther 6: 1497-1501, 1995.
33. Chao J, Jin L, Chen L-M, Chen VC, and Chao L: Systemic and portal vein delivery of human kallikrein gene reduces blood pressure in hypersensitive rats. Hum Gene Ther 7: 901-911, 1996.
34. Motokura T, Bloom T, Kim HG, Jüppner H, Ruderman JV, Kronenberg HM, and Arnold A: A novel cyclin encoded by a bcl1- linked candidate oncogene. Nature 350: 512-515, 1991.
35. Auvinen M, Paasinen-Sohns A, Hirai H, Andersson LC, and Holtta E: Ornithine decarboxylase- and ras- induced cell transformations: reversal by protein tyrosine kinase inhibitors and role of pp130CAS. Mol Cell Biol 15: 6513-6525, 1995.
36. Capon DJ, Chen EY, Levinson AD, Seeburg PH, and Goeddel DV: Complete nucleotide sequences of the T24 human bladder carcinoma oncogene and its normal homologue. Nature 302: 33-37, 1983.
37. Spandidos DA and Wilkie NM: Malignant transformation of early passage rodent cells by a single mutated human oncogene. Nature 310: 469-475, 1984.
38. Barbacid M: ras genes. Annu Rev Biochem 56: 779-827, 1987.
39. Hayday AC, Gillies SD, Saito H, Wood C, Wiman K, Hayward WS, and Tonegawa S: Activation of a translocated human c-myc gene by an enhancer in the immunoglobulin heavy-chain locus. Nature 307: 334-340, 1984.
40. Hunger SP, Ohyashiki K, Toyama K, and Cleary ML: HIf, a novel hepatic bZIP protein, shows altered DNA-binding properties following fusion to E2A in t(17;19) acute lymphoblastic leukemia. Genes Dev 6: 1608-1620, 1992.
41. Kamps MP, Look AT, and Baltimore D: The human t(1;19) translocation in pre-B ALL produces multiple nuclear E2A-Pbx1 fusion proteins with differing transforming potentials. Genes and Dev 5: 358-368, 1991.
42. Kakizuka A, Miller WHJr., Umesono K, Warrell RPJr., Frankel SR, Murty WS, Dmitrovsky E, and Evans RM: Chromosomal translocation t(15;17) in acute promyelocytic leukemia fuses RARa with a novel putative transcription factor, PML. Cell 66: 663-674, 1991.
43. Boulikas T: A model of transcription/replication enhancers. Oncol Rep 2: 171-181, 1995.
44. Culver KW, Ram Z, Wallbridge S, Ishii H, Oldfield EH, and Blaese RM: In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors. Science 256: 1550-1552, 1992.
45. Jiao S, Gurevich V and Wolff JA: Long-term correction of rat model of Parkinson's disease by gene therapy. Nature 362: 450-453, 1993.
46. Fang B, Eisensmith RC, Wang H, Kay MA, Cross RE, Landen CN, Gordon G, Bellinger DA, Read MS, Hu PC, Brinkhous KM, and Woo SLC: Gene therapy for hemophilia B: host immunosuppression prolongs the therapeutic effect of adenovirus- mediated factor IX expression. Hum Gene Ther 6: 1039-1044, 1995.
47. Pochon NA-M, Heyd B, Déglon N, Joseph J-M, Zurn AD, Baetge EE, Hammang JP, Goddard M, Lysaght M, Kaplan F, Kato AC, Schluep M, Hirt L, Regli F, Porchet F, and de Tribolet N: Clinical Protocol: gene therapy for amyotrophic lateral sclerosis (ALS) using a polymer-encapsulated xenogenic cell line engineered to secrete hCNTF. Hum Gene Ther 7: 851-860, 1996.
48. Greber UF, Webster P, Weber J, and Helenius A: The role of the adenovirus protease in virus entry into cells. EMBO J 15: 1766- 1777, 1996.
49. Wagner E, Zatloukal K, Cotten M, Kirlappos H, Mechtler K, Curiel DT, and Birnstiel ML: Coupling of adenovirus to tranferrin- polylysine/DNA complexes greatly enhances receptor-mediated gene delivery and expression of transfected genes. Proc Natl Acad Sci USA 89: 6099-6103, 1992.
50. Kotin RM, Siniscalco M, Samulski RJ, Zhu X, Hunter L, Laughlin CA, McLaughlin S, Muzyczka N, Rocchi M, and Berns KI: Site- specific integration by adeno-associated virus. Proc Natl Acad Sci USA 87: 2211-2215, 1990.
51. Clark KR, Voulgaropoulou F, Fraley DM, and Johnson PR: Cell lines for the production of recombinant adeno-associated virus. Hum Gene Ther 6: 1329-1341, 1995.
52. Hermonat PL, and Muzyczka N: Use of adeno-associated virus as a mammalian DNA cloning vector: transduction of neomycin resistance into mammalian tissue culture cells. Proc Natl Acad Sci USA 81: 6466-6470, 1984.
53. Chatterjee S, Johnson PR, and Wong KK: Dual target inhibition of HIV-1 in vitro by means of an adeno-associated virus antisense vector. Science 258: 1485-1488, 1992.
54. Walsh CE, Nienhuis AW, Samulski RJ, Brown MG, Miller JL, Young NS, and Liu JM: Phenotypic correction of Fanconi anemia in human hematopoietic cells with a recombinant adeno-associated virus vector. J Clin Invest 94: 1440-1448, 1994.
55. Russell DW, Alexander IE, and Miller AD: DNA synthesis and topoisomerase inhibitors increase transduclion by adeno-associated virus. Proc Natl Acad Sci USA 92: 5719-5723, 1995.
56. Gregoriadis G and Neerunjun ED: Homing of liposomes to target cells. Biochem Biophys Res Comm 65: 537-544, 1975.
57. Gabizon A, Catane R, Uziely B, Kaufman B, Safra T, Cohen R, Martin F, Huang A and Barenholz Y: Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes. Cancer Res 54: 987-992, 1994.
58. Lee RJ and Low PS: Folate-mediated tumor cell targeting of liposome-entrapped doxorubicin in vitro. Biochim Biophys Acta 1233: 134-144, 1995.
59. Straubinger RM, Lopez NG, Debs RJ, Hong K and Papahadjopoulos D: Liposome-based therapy of human ovarian cancer: parameters determining potency of negatively charged and antibody-targeted liposomes. Cancer Res 48: 5237-5245, 1988.
60. Ahmad I, Longenecker M, Samuel J and Allen TM: Antibody- targeted delivery of doxorubicin entrapped in sterically stabilized liposomes can eradicate lung cancer in mice. Cancer Res 53: 1484- 1488, 1993.
61. Mayer LD, Tai LCL, Ko DSC, Masin D, Ginsberg RS, Cullis PR and Bally MB: Influence vesicle size, lipid composition, and drug- to-lipid ratio on the biological activity liposomal doxorubicin in mice. Cancer Res 49: 5922-5930, 1989.
62. Papahadjopoulos D, Allen TM, Gabizon A, Mayhew E, Matthay K, Huang SK, Lee K-D, Woodle MC, Lasic DD, Redemann C and Martin FJ: Sterically stabilized liposomes: Improvements in pharmacokinetics and antitumor therapeutic efficacy. Proc Natl Acad Sci USA 88: 11460-11464, 1991.
63. Lasic D and Martin F: Editors in "Stealth liposomes"CRC Press Boca Raton Florida, pp 1-289, 1995.
64. Huang SK, Martin FJ, Jay G, Vogel J, Papahadjopoulos D, and Friend DS: Extravasastion and transcytosis of liposomes in Kaposi's sarcoma-like dermal lesions of transgenic mice bearing the HIV Tat gene. Am J Pathol 143: 10-14, 1993.
65. Lasic D and Papahadjopoulos D: Liposomes revisited. Science 267: 1275-1276, 1995.
66. Bally MB, Nayar R, Masin D, Hope MJ, Cullis PR and Mayer LD: Liposomes with entrapped doxorubicin exhibit extended blood residence times. Biochim Biophys Acta 1023: 133-139, 1990.
67. Hsieh W-S and Simons JW: Tumor review. Sustemic therapy of prostate cancer. New concepts from prostate cancer tumor biology. Cancer Treatm Rev 19: 229-260, 1993.
68. Wang C-Y and Huang L: pH-sensitive immunoliposomes mediate target-cell-specific delivery and controlled expression of a foreign gene in mouse. Proc Natl Acad Sci USA 84: 7851-7855, 1987.
69. Kaneda Y, Iwai K, and Uchida T: Increased expression of DNA cointroduced with nuclear protein in adult rat liver. Science 243: 375-378, 1989.
70. Thierry AR and Dritschilo A: Intracellular availability af unmodified, phosphorothioated and liposomally encapsulated oligodeoxynucleotides for antisense activity. Nucleic Acids Res 20: 5691-5698, 1992.
71. Felgner PL, Gadek TR, Holm M, Roman R, Chan HW, Wenz M, Northrop JP, Ringold GM, and Danielsen M: Lipofection: a highly efficient, lipid-mediated DNA-transfection procedure. Proc Natl Acad Sci USA 84: 7413-7417, 1987.
72. Behr J-P, Demeneix B, Loeffler J-P, and Perez-Mutul J: Efficient gene transfer into mammalian primary endocrine cells with lipopolyamine-coated DNA. Proc Natl Acad Sci USA 56: 6982- 6986, 1989.
73. Aliño SF, Bobadilla M, Crespo J, and Lejarreta M: Human α1- antitrypsin gene transfer to in vivo mouse hepatocytes. Hum Gene Ther 7: 531-536, 1996.
74. Ledley FD: Nonviral gene therapy: the promise of genes as pharmaceutical products. Hum Gene Ther 6: 1129-1144, 1995.
75. Lasic DD and Templeton NS: Liposomes in gene therapy. Adv Drug Del Rev, in the press, 1996.
76. Wagner E, Plank C, Zatloukal K, Cotten M, and Birnstiel ML: Influenza virus hemagglutinin HA-2 N-terminal fusogenic peptides augment gene transfer by transferrin-polylysine-DNA complexes: toward a synthetic virus-like gene-transfer vehicle. Proc Natl Acad Sci USA 89: 7934-7938, 1992.
77. Zhu N, Liggitt D, Liu Y, and Debs R: Systemic gene expression after intravenous DNA delivery into adult mice. Science 261: 209-211, 1993.
78. Schwartz B, Benoist C, Abdallah B, Scherman D, Behr J-P, and Demeneix BA: Liposperminebased gene transfer into the newborn mouse brain is optimized by a low lipospermine/DNA charge ratio. Hum Gene Ther 6: 1515-1524, 1995.
79. Gottschalk S, Christiano RJ, Smith LC, and Woo SLC: Folate receptor mediated DNA delivery into tumor cells: potosomal disruption results in enhanced gene expression. Gene Ther 1: 185-191, 1993.
80. Robins SM, Quintrell NA, and Bishop JM: Myristoylation and differential palmitoylation of the HCK protein-tyrosine kinases govern their attachment to membranes and association with caveolae. Mol Cell Biol 15: 3507-3515, 1995.
81. Andersen RGW: Caveolae: Where incoming and outgoing messengers meet. Proc Natl Acad Sci USA 90: 10909-10913, 1993.
82. Lisanti MP, Scherer PE, Tang Z and Sargiacomo M: Caveolae, caveolin and caveolin-rich membrane domains: a signalling hypothesis. Trends Cell Biol 4: 231-235, 1994.
83. Curiel DT, Agarwal S, Wagner E, and Cotten M: Adenovirus enhancement of transferrrinpolylysine-mediated gene delivery. Proc Natl Acad Sci USA 88: 8850-8854, 1991.
84. Cotten M, Wagner E, Zatloukal K, Phillips S, Curiel DT, and Birnstiel ML: High efficiency receptor-mediated delivery of small and large (48 kilobase) gene constructs using the endosome disruption activity of defective or chemically inactivated adenovirus particles. Proc Natl Acad Sci USA 89: 6094-6098, 1992.
85. Boulikas T: Nuclear localization signals (NLS). Crit Rev Eukar Gene Expression 3: 193-227, 1993.
86. Richards CA, Austin EA, and Huber BE: Transcriptional regulatory sequences of carcinoembryonic antigen: identification and use with cytosine deaminase tumor-specific gene therapy. Hum Gene Ther 881-893, 1995.
87. Su H, Chang JC, Xu SM, and Kan YW: Selective killing of AFP- positive hepatocellular carcinoma cells by adeno-associated virus transfer of ther herpes simplex virus thvmidine kinase gene. Hum Gene Ther 7: 463-470, 1996.
88. Gallo RC, and Mahan LC: 88 Thierry AR, Lunardi-Iskandar Y, Bryant JL, Rabinovitch P, Systemic gene therapy: biodistribution and long-term expression of a transgene in mice. Proc Natl Acad Sci USA 92: 9742-9746, 1995.
89. Lew D, Parker SE, Latimer T, Abai AM, Kuwahara-Rundell A, Don SG, Yang Z-Y, Laface D, Gromkowski SH, Nabel GJ, Manthorpe M, and Norman J: Cancer gene therapy using plasmid DNA: pharmacokinetic study of DNA following injection in mice. Hum Gene Ther 6: 553-564, 1995.
90. Boulikas T: Common structural features of replication origins in all life forms. J Cell Biochem 60: 297-316, 1996.
91. Gassmann M, Donoho G, and Berg P: Maintenance of an extra- chromosomal plasmid vector in mouse embryonic stem cells. Proc Natl Acad Sci USA 92: 1292-1296, 1995.
92. Boulikas T, Hsie L, Kong CF, Hu J, Brooks D, and Zannis- Hadjopoulos M: The 5′ regulatory region of the human choline acetyltransferase gene is anchored to the nuclear matrix and has origin of replication activity. Submitted, 1996.
93. Boulikas T: Chromatin domains and prediction of MAR sequences. Int Rev Cytol 1 62A: 279-388, 1995.
94. Cooney M, Czernuszewicz G, Postal EH, Flint SJ, and Hogan ME: Site-specific oligonucleotide binding represses transcription of the human c-myc gene in vitro. Science 241: 456-459, 1988.
95. Maher LJIII, Dervan PB, and Wold B: Analysis of promoter- specific repression by triplehelical DNA complexes in a eukaryotic cell-free transcription system. Biochemistry 31: 70-81, 1992.
96. Ing NH, Beekman JM, Kessler DJ, Murphy M, Jayaraman K, Zendegui JG, Hogan ME, O'Malley BW, and Tsai M-J: In vivo transcription of a progesterone responsive gene is specifically inhibited by a triplex-forming oligonucleotide. Nucleic Acids Res 21: 2789-2796, 1993.
97. Postel EH, Flint SJ, Kessler DJ and Hogan ME: Evidence that a triplex-forming oligodeoxyribonucleotide binds to the c-muc promoter in HeLKa cells therby reducing c-myc mRNA levels. Proc Natl Acad Sci USA 88: 8227-8231, 1991.
98. Wang G, Levy D, Seidman MM, and Glazer PM: Targeted mutagenesis in mammalian cells mediated by intracellular triple helix formation. Mol Cell Biol 15: 1759-1768, 1995.
99. Francois J-C, Saison-Behmoaras T, Thuong NT, and Helene C: Inhibition of restriction endonuclease cleavage via triple helix formation by homopyrimidine oligonucleotides. Biochemistry 28: 9617-9619, 1989.
100. Hacia JG, Dervan PB, and Wold BJ: Inhibition of Klenow fragment of DNA polymerase on double-helical templates by oligonucleotide-directed triple-helix formation. Biochemistry 33: 6192-6200, 1994.
101. Dayn A, Samadashwily GM, and Mirkin SM: Intramolecular DNA triplexes: unusual sequence requirements and influence on DNA polymerization. Proc Natl Acad Sci USA 89: 11406-11410, 1992.
102. Baran N, Lapidot A, and Manor H: Formation of DNA triplexes accounts for arrests of DNA synthesis at d(TC)n and d(GA)n tracts. Proc Natl Acad Sci USA 88: 507-511, 1991.
103. Young SL, Krawczyk SH, Matteucci MD, and Toole JJ: Triple helix formation inhibits transcription elongation in vitro. Proc Natl Acad Sci USA 88: 10023-10026, 1991.
104. Moser HE and Dervan PB: Sequence-specific cleavage of double- helical DNA by triple helix formation. Science 238: 645-650, 1987.
105. Pei D, Corey DR, and Schultz PG: Site-specific cleavage of duplex DNA by a semisynthetic nuclease via triple-helix formation. Proc Natl Acad Sci USA 87: 9858-9862, 1990.
106. Sun J-S and Helene C: Oligonucleotide-directed triple-helix formation. Curr Opin Struct Biol 3: 345-356, 1993.
107. Zelphati O, Imbach J-L, Signoret N, Zon G, Rayner B, and Leserman L: Antisense oligonucleotides in solution or encapsulated in immunoliposomes inhibit replication of HIV-1 by several different mechanisms. Nucleic Acids Res 22: 4307-4314, 1994.
108. Bongartz J-P, Aubertin A-M, Milhaud PG, and Lebleu B: Improved biological activity of antisense oligonucleotides conjugated to a fusogenic peptide. Nucleic Acids Res 22: 4681-4688, 1994.
109. Rosenberg SA, Packard BS, Aebersold PM, Solomon D, Topalian SL, Toy ST, Simon P, Lotze MT, Yang JC, Seipp CA, Simpson C, Carter C, Bock S, Schwartzentruber D, Wei JP, and White DE: Use of tumor infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. N Engl J Med 319: 1676-1680, 1988.
110. Rosenberg, SA, Anderson WF, Blaese MR, Ettinghausen SE, Hwu P, Karp SE, Kasid A, Mule JJ, Parkinson DR, Salo JC, Schwartzentruber DJ, Topalian SI, Weber JS, Yannelli JR, Yang JC, and Linehan WM: Initial proposal of clinical research project. Immunization of cancer patients using autologous cancer cells modified by insertion of the gene for interleukin-2. Hum Gene Ther 3: 75-90, 1992.
111. Cassileth PA, Podack E, Sridhar K, Savaraj N, and Hanlon J: Phase I study of transfected cancer cells expressed in the interleukin-2 gene product in limited stage small cell lung cancer. Hum Gene Ther 6: 369-383, 1995.
112. Vieweg J, Rosenthal F, Bannerji R, Heston W, Fair W, Gansbacher B, and Gilboa E: Immunotherapy of prostate cancer in the Dunning rat model: use of cytokine gene modified tumor vaccines. Cancer Res 54: 1760-1765, 1994.
113. El-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, Lin D, Mercer WE, Kinzler KW and Vogelstein B: WAFI, a potential mediator of p53 tumor suppression. Cell 75: 817-825, 1993.
114. Kastan MB, Zhan Q, El-Deiry WS, Carrier F, Jacks T, Walsh WV, Plunkett BS, Vogelstein B and Fornace AJ: A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia. Cell 71: 587-597, 1992.
115. Okamoto K and Beach D: Cyclin G is a transcriptional target of the p53 tumor suppressor protein. EMBO J 13: 4816-4822, 1994.
116. Perry ME, Piette J, Zawadzki JA, Harvey D and Levine AJ: The mdm-2 gene is induced response to UV light in a p53-dependent manner. Proc Natl Acad Sci USA 90: 11623-11627 1993.
117. Shivakumar CV, Brown DR, Deb S, and Deb SP: Wild-type human p53 transactivates the human proliferating cell nuclear antigen promoter. Mol Cell Biol 1 5: 6785-6793, 1995.
118. Zambetti GP, Bargonetti J, Walker K, Prives C, and Levine AJ: Wild-type p53 mediates positive regulation of gene expression through a specific DNA sequence element. Genes Dev 6: 1143- 1152, 1992.
119. Deb SP, Muñoz RM, Brown DR, Subler MA, and Deb S: Wild-type human p53 activates the human epidermal growth factor receptor promoter. Oncogene 9: 1341-1349, 1994.
120. Miyashita T and Reed JC: Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell 80: 293-299, 1995.
121. Oliner JD, Kinzler KW, Meltzer PS, George DL, and Vogelstein B: Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature 358: 80-83, 1992.
122. Fukasawa K, Choi T, Kuriyama R, Rulong S, and Vande Woude GF: Abnormal centrosome amplification in the absence of p53. Science 271: 1744-1747, 1996.
123. Deb S, Jackson CT, Subler MA, and Martin DW: Modulation of cellular and viral promoters by mutant human p53 proteins found in tumor cells. J Virol 66: 6164-6170, 1992.
124. Shivakumar CV, Brown DR, Deb S, and Deb SP: Wild-type human p53 transactivates the human proliferating cell nuclear antigen promoter. Mol Cell Biol 15: 6785-6793, 1995.
125. Chin K-V, Ueda K, Pastan I, and Gottesman MM: Modulation of activity of the promoter of the human MDRI gene by Ras and p53. Science 255: 459-462, 1992.
126. Zastawny RL, Salvino R, Chen J, Benchimol S, and Ling V: The core promoter region of the P-glycoprotein gene is sufficient to confer differential responsiveness to wild-type and mutant p53. Oncogene 8: 1529-1535, 1993.
127. ' 127 Tsutsumi-Ishi Y,. Tadokoro K, Hanaoka F, and Tsuchida N: Response of heat shock element with the human HSP70 promoter to mutated p53 genes. Cell Growth Differ 6: 1-8, 1995.
128. Zambetti GP and Levine AJ: A comparison of the biological activities of wild-type and mutant p53. FASEB J 7: 855-865, 1993.
129. Deffie A, Wu H, Reinke V, and Lozano G: The tumor suppressor p53 regulates its own transcription. Mol Cell Biol 13: 3415-3423, 1993.
130. Stuart E, Haffner R, Oren M, and Gruss P: Loss of p53 function through PAX-mediated transcriptional repression. EMBO J 14: 5638-5645, 1995.
131. Shivakumar CV, Brown DR, Deb S, and Deb SP: Wild-type human p53 transactivates the human proliferating cell nuclear antigen promoter. Mol Cell Biol 15: 6785-6793, 1995.
132. El-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, Lin D, Mercer WE, Kinzler KW and Vogelstein B: WAFI, a potential mediator of p53 tumor suppression. Cell 75: 817-825, 1993.
133. Miller SD, Farmer G, and Prives C: p53 inhibits DNA replication in vitro in a DNA-binding-dependent manner. Mol Cell Biol 15: 6554-6560, 1995.
134. van den Heuvel SJL, van Laar T, Kast WM, Melief CJM, Zantema A and van der Eb AJ: Association between the cellular p53 and the adenovirus 5 EIB-SSkd proteins reduces the oncogenicity of Ad- transformed cells. EMBO J 9: 2621 -2629, 1990.
135. Lane DP and Crawford LV: T antigen is bound to a host protein in SV40 transformed cells. Nature 278: 261-263, 1979.
136. Werness BA, Levine AJ and Howley PM: Association of human papillomavirus types 16 and 18 E6 proteins with p53. Science 248: 76-79, 1990.
137. Yew PR and Berk AJ: Inhibition of p53 transactivation required for transformation by adenovirus early IB protein. Nature 357: 82-85, 1992.
138. Kuerbitz SJ, Plunkett BS, Walsh WV and Kastan MB: Wild-type p53 is a cell cycle checkpoint determinant following irradiation. Proc Natl Acad Sci USA 89: 7491-7495, 1992.
139. Kastan MB, Onyekwere O, Sidransky D, Vogelstein B and Craig RW: Participation of p53 protein in the cellular reponse to DNA damage. Cancer Res 51: 6304-6311, 1991.
140. Tishler RB, Calderwood SK, Coleman CN and Price BD: Increases in sequence specific DNA binding by p53 following treatment with chemotherapeutic and DNA damaging agents. Cancer Res 53: 2212-2216, 1993.
141. Nelson WG and Kastan MB: DNA strand breaks: the DNA template alterations that trigger p53-dependent DNA damage response pathways. Mol Cell Biol 14: 1815-1823, 1994.
142. Li R and Botchan MR: The acidic transcriptional activation domains of VP16 and p53 bind the cellular replication protein A and stimulate in vitro BPV- 1 DNA replication. Cell 73: 1207-1221, 1993.
143. Dutta A, Ruppert JM, Aster JC and Winchester E: Inhibition of DNA replication factor RPA by p53. Nature 365: 79-82, 1993.
144. Xiao H, Pearson A, Coulombe B, Truant R, Zhang S, Regier JL, Thezenberg SJ, Reinberg D, Flores O, Ingles CJ and Greenblatt J: Binding of basal transcription factor TFIIH to the acidic activation domains of VP16 and p53. Mol Cell Biol 14: 7013-7024, 1994.
145. Wang Z, Svejstrup JQ, Feaver WJ, Wu X, Kornberg RD and Friedberg EC: Transcription factor b (TFIIH) is required during nucleotide excision repair in yeast. Nature 368: 74-76, 1994.
146. Lee S, Elenbaas B, Levine A and Griffith J: p53 and its 14 kDa C-terminal domain recognize primary DNA damage in the form of insertion/deletion mismatches. Cell 81: 1013-1020, 1995.
147. Lu X and Lane DP: Differential induction of transcriptionally active pS3 following UV or ionizing radiation: defects in chromosome instability syndromes? Cell 75: 765-778, 1993.
148. Boulikas T: The nonuniform repair of active and inactive chromatin domains, Int J Oncol 8: 65-75, 1996.
149. Stürzbecher H-W, Donzelmann B, Henning W, Knippschild U, and Buchhop S: p53 is linked directly to homologous recombination processes via RAD51/RecA protein interaction. EMBO J 15: 1992-2002, 1996.
150. Donehower LA, Harvey M, Slagle BL, McArthur MJ, Montgomery CA Jr, Butel JS, and Bradley A: Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature 356: 215-221, 1992.
151. Savitsky K, Bar-Shira A, Gilad S, Rotman G, Ziv Y, Vanagaite L, Tagle DA, Smith S, Uziel T, Sfez S, Ashkenazi M, Pecker I, Frydman M, Harnik R, Patanjali SR, Simmons A, Clines GA, Sartiel A, Gatti RA, Chessa L, Sanal O, Lavin MF, Jaspers NGJ, Taylor AMR, Arlett CF, Miki T, Weissman SM, Lovett M, Collins FS, and Shiloh Y: A single ataxia telangiecstasia gene with a product similar to PI-3 kinase. Science 268: 1749-1753, 1995.
152. Seto E, Usheva A, Zambetti GP, Momand J, Horikoshi N, Weinmann R, Levine AJ, and Shenk T: Wild-type p53 binds to the TATA-binding protein and represses transcription. Proc Natl Acad Sci USA 89: 12028-12032, 1992.
153. Truant R, Xiao H, Ingles J, and Greenblatt J: Direct interaction between the transcriptional activation domain of human p53 and the TATA box-binding protein. J Biol Chem 268: 2284-2287, 1993.
154. Shen Y and Shenk T: Relief of p53-mediated transcriptional repression by the adenovirus EIB 19-kDa protein or the cellular Bcl-2 protein. Proc Natl Acad Sci USA 91: 8940-8944, 1994.
155. White E: Death-defying acts: a meeting review on apoptosis. Genes Dev 7: 2277-2284, 1993.
156. Clarke AR, Purdie CA, Harrison DJ, Morris RG, Bird CC, Hooper ML and Wyllie AH: Thymocyte apoptosis induced by p53-dependent and independent pathways. Nature 362: 849-852, 1993.
157. Gottlieb E, Hafner R, von Ruden T, Wagner EF, and Oren M: Down-regulation of wild-type p53 activity interferes with apoptosis of IL-3 dependent hematopoietic cells following TL-3 withdrawal. EMBO J 13: 1368-1374, 1994.
158. 158a Lowe SW, Schmitt EM, Smith SW, Osborne BA and Jacks T: p53 is required for radiation-induced apoptosis in mouse thymocytes. Nature 362: 847-849, 1993.
159. 158b Lowe S and Ruley HE: Stabilization of the p53 tumor suppressor is induced by adenovirus-5 E1A and accompanies apoptosis. Genes Dev 7: 535-545, 1993.
160. Debbas M and White E: Wild-type p53 mediates apoptosis by E1A, which is inhibited by E1B. Genes Dev 7: 546-554, 1993.
161. Hermeking H and Eick D: Mediation of c-Myc-induced apoptosis by p53. Science 265: 2091-2093, 1994.
162. Waf1/cip1 Genes Dev 8: 2817-2830, 1994.
163. Chiou S, Rao L, and White E: Bcl-2 blocks p53-dependent apoptosis. Mol Cell Biol 14: 1556-1563, 1994.
164. Ziegler A, Jonason AS, Leff'ell DJ, Simon-JA, Sharma HW, Kimmelman J, Remington L, Jacks T, and Brash DE: Sunburn and p53 in the onset of skin cancer. Nature 372: 773-776, 1994.
165. Graeber TG, Osmanian C, Jacks T, Housman DE, Koch CJ, Lowe SW, and Giaccia AJ: Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours. Nature 379: 88-91, 1996.
166. Merritt AJ, Potten CS, Kemp CJ, Hickman JA, Balmain A, Lane DP, and Hall PA: The role of p53 in spontaneous and radiation-induced apoptosis in the gastrointestinal tract of normal and p53-deficient mice. Cancer Res 54: 614-617, 1994.
167. Caelles C, Helmberg A, and Karin M: p53-dependent apoptosis in the absence of transcriptional activation of p53-target genes. Nature 370: 220-223, 1994.
168. Ko LJ and Prives C: p53: puzzle and paradigm. Genes Dev 10: 1054-1072, 1996.
169. Hiebert SW, Packham G, Strom DK, Haffner R, Oren M, Zambetti G, and Cleveland JL: E2F-1:DP-1 induces p53 and overrides survival factors to trigger apoptosis. Mol Cell Biol 15: 6864-6874, 1995.
170. Field SJ, Tsai F-Y, Kuo F, Zubiaga AM, Kaelin WG Jr, Livingston DM, Orkin SH, and Greenberg ME: E2F-1 functions in mice to promote apoptosis and suppresses proliferation. Cell 85: 549-561, 1996.
171. Yuan J Shaham S, Ledoux S, Ellis HM, and Horvitz HR: The C. elegans cell death gene ced3 encodes a protein similar to mammalian interleukin- 1β-converting enzyme. Cell 75: 641-652, 1993.
172. Miura M, Zhu H, Rotello R, Hartwieg EA, and Huan J: Induction of apoptosis in fibroblasts by IL-1β-converting enzyme, a mammalian homolog of the C. elegans cell death gene ced-3. Cell 75: 653-660, 1993.
173. Kuida K, Lippke JA, Ku G, Harding MW, Livingston DJ, Su MS-S, and Flavell RA: Altered cytokine export and apoptosis in mice deficient in interleukin- Iβ converting enzyme. Science 267: 2000-2003, 1995.
174. Troy CM, Stefanis L, Prochiantz A, Greene LA, and Shelanski ML: The contrasting roles of ICE family proteases and interleukin- 1β in apoptosis induced by trophic factor withdrawal and by copper/zinc superoxide dismutase down-regulation. Proc Natl Acad Sci USA 93: 5635-5640, 1996.
175. 1 arrest of Saccharomyces cerevisiae. Gene Dev 10: 382-394, 1996.
176. Voeller HJ, Sugars LY, Pretlow T, and Gelmann EP: p53 mutations in human prostate cancer specimens. J Urol 151: 492-495, 1994.
177. Isaacs WB, Bova GS, Morton RA, Bussemakers MJG, Brooks JD, and Ewing CM: Molecular biology of prostate cancer. Semin Oncol 21: 514-521, 1994.
178. Chi SG, de Vere White RW, Meyers FJ, Siders DB, Lee F, and Gumerlock PH: p53 in prostate cancer: frequent expressed transition mutations. J Natl Cancer Inst 86: 926-933, 1994.
179. Dinjens WN, van der Weiden MM, Schroeder FH, Bosman FT, and Trapman J: Frequency and characterization of p53 mutations in primary and metastatic human prostate cancer. Int J Cancer 56: 630-633, 1994.
180. Isaacs WB, Carter BS, and Ewing CM: Wild-type p53 suppresses growth of human prostate cancer cells containing mutant p53 alleles. Cancer Res 51: 4716-4720, 1991.
181. Bacchetti S and Graham FL: Inhibition of cell proliferatioin by an adenovirus vector expressing the human wild-type p53 protein. Int J Oncol 3: 781-788, 1993.
182. Fujiwara T, Cai DW, Georges RN, Mukhopadhyay T, Grimm EA, and Roth JA: Therapeutic effect of a retroviral wild-type p53 expression vector in an orthotopic lung cancer model. J Natl Cancer Inst 86: 1458-1462, 1994.
183. Lesoon-Wood LA, Kim WH, Kleinman HK, Weintraub BD, and Mixson AJ: Systemic gene therapy with p53 reduces growth and metastases of a malignant human breast cancer in nude mice. Hum Gene Ther 6: 395-405, 1995.
184. Stuart E, Haffner R, Oren M, and Gruss P: Loss of p53 function through PAX-mediated transcriptional repression. EMBO J 14: 5638-5645, 1995.
185. Wu L, Bayle JH, Elenbaas B, Pavletich NP and Levine AJ: Alternatively spliced forms in the carboxy-terminal domain of the p53 protein regulate its ability to promote annealing of complementary single strands of nucleic acids. Mol Cell Biol 15: 497-504, 1995.
186. Jayaraman L and Prives C: Activation of p53 sequence-specific DNA binding by short single strands of DNA requires the p53 C-terminus. Cell 81: 1021-1029, 1995.
187. Eastham JA, Hall SJ, Sehgal I, Wang J, Timme TL, Yang G, Connell-Crowley L, Elledge SJ, Zhang W-W, Harper JW, and Thompson TC: In vivo gene therapy with p53 or p21 adenovirus for prostate cancer. Cancer Res 55: 5151-5155, 1995.
188. Yang C, Cirielli C, Capogrossi MC, and Passaniti A: Adenovirus-mediated wild-type p53 expression induces apoptosis and suppresses tumorigenesis of prostatic tumor cells. Cancer Res 55: 4210-4213, 1995.
189. Bookstein R, Shew J-Y, Chen P-L, Scully P, and Lee W-H: Suppression of tumorigenicity of human prostate carcinoma cells by replacing a mutated RB gene. Science 247: 712-715, 1990.
190. Borrelli E, Heyman R, Hsi M, and Evans RM: Targeting of an inducible toxic phenotype in animal cells. Proc Natl Acad Sci USA 85: 7572-7576, 1988.
191. Kimura H, Sakamoto T, Cardillo JA, Spee C, Hinton DR, Gordon EM, Anderson WF, and Ryan SJ: Retrovirus-mediated suicide gene transduction in the vitrous cavity of the eye: feasibility in prevention of proliferative vitreoretinopathy. Hum Gene Ther 7: 799-808, 1996.
192. Eastham JA, Chen S-H, Sehgal I, Yang G, Timme TL, Hall SJ, Woo SLC, and Thompson TC: Prostate cancel gene therapy: herpes simplex virus thymidine kinase gene transduction followed by ganciclovir in mouse and human prostate cancer models. Hum Gene Ther 7: 515-523, 1996.
193. Dimaio JM, Clary BM, Via DF, Coveney E, Papas TN, and Lyerly HK: Directed enzyme prodrug gene therapy for pancreatic cancer in vivo. Surgery 116: 205-213, 1994.
194. Austin EA and Huber BH: A first step in the development of gene therapy for colorectal carcinoma: cloning, sequencing, and expression of Escherichia coli cytosine deaminase. Mol Pharmacol 43: 380-387, 1993.
195. Richards CA, Austin EA, and Huber BE: Transcriptional regulatory sequences of carcinoembryonic antigen: identification and use with cytosine deaminase for tumor-specific gene therapy. Hum Gene Ther 6: 881-893, 1995.
196. Meyerson M, Enders GH, Wu C-L, Su L-K, Gorka C, Nelson C, Harlow E and Tsai L- H: A family of human cdc2-related protein kinases. EMBO J 11: 2909-2917, 1992.
197. Tsai L-H, Lees E, Faha B, Harlow E and Riabowol K: The cdk2 kinase is required for the Gl-to-S transition in mammalian cells. Oncogene 8: 1593-1602, 1993.
198. Slingerland JM, Hengst L, Pan C-H, Alexander D, Stampfer MS and Reed SI: A novel inhibitor of cyclin-cdk activity detected in transforming growth factor β-arrested epithelial cells. Mol Cell Biol 14: 3683-3694, 1994.
199. Hunter T and Karin M: The regulation of transcription by phosphorylation. Cell 70: 375-387, 1992.
200. Boulikas T: Control of DNA replication by protein phosphorylation. Anticancer Res 14: 2465-2472, 1994.
201. Lammie GA, Fantl V, Smith R, Schuuring E, Brookes S, Michalides R, Dickson C, Arnold A and Peters G: D11S287, a putative oncogene on chromosome 11q13, is amplified and expressed in squamous cell and mammary carcinomas and linked to BCL-1. Oncogene 6: 439-444, 1991.
202. Motokura T, Bloom T, Kim HG, Jüppner H, Ruderman JV, Kronenberg HM and Arnold A: A novel cvclin encoded by a bcl1-linked candidate oncogene. Nature 350: 512-515, 1991.
203. Resnitzky D, Gossen M, Bujard H and Reed SI: Acceleration of the GI/S phase transition by expression of cyclins D1 and E with an inducible serum. Mol Cell Biol 14: 1669-1679, 1994.
204. Xiong Y, Zhang H and Beach D: D type cyclins associate with multiple protein kinases and the DNA replication and repair factor HCNA. Cell 71: 505-514, 1992.
205. 1. Nature 328: 445-449, 1987.
206. Lüscher B, Kuenzel EA, Krebs EG and Eisenman RN: Myc oncoproteins are phosphorylated by casein kinase II. EMBO J 8: 1111-1119, 1989.
207. Fotedar R and Roberts JM: Cell cycle regulated phosphorylation of RPA-32 occurs within the replication initiation complex. EMBO J 11: 2177-2187, 1992.
208. Din S-U, Brill SJ, Fairman MP and Stillman B: Cell-cycle-regulated phosphorylation of DNA replication factor A from human and yeast cells. Genes Dev 4: 968-977, 1990.
209. Firzlaff JM, Galloway DA, Eisenman RN, and Luscher B: The E7 protein of human papillomavirus type 16 is phosphorylated by casein kinase II. New Biologist 1: 44-53, 1989.
210. Shirodkar S, Ewen M, DeCaprio JA, Morgan J, Livingston DM and Chittenden T: The transcription factor E2F interacts with the retinoblastoma product and a p107-cyclin A complex in a cell cycle-regulated manner. Cell 68: 157-166, 1992.
211. cdk2 the E2F-cyclin a complex. Cell 68: 167-176, 1992.
212. Gottesman MM amd Pastan I: The multidrug transporter, a double-edged sword. J Biol Chem 263: 12163-12166, 1988.
213. Ward M, Richardson C, Piuoli P, Smith L, Podda S, Goff S, Hesdorffer C, and Bank A: Transfer and expression of the human multiple drug resistance gene in human CD34+ cells. Blood 84: 1408-1414, 1994.
214. Koutsilieris M, Dimopoulos M-A. Doillon C, Sourla A, ReyesMoreno C, and Choki I: Review. The molecular concepts of prostate cancer. 1996.
215. Bidwell JP, Fey EG, van Wijnen AJ, Penman S, Stein JL, Lian JB, and Stein GS: Nuclear matrix proteins distinguish normal diploid osteohlasts from osteosarcoma cells. Cancer Res 54: 28-32, 1994.
216. Keesee SK, Meneghini MD, Szaro RP, and Wu Y-J: Nuclear matrix proteins in human colon cancer. Proc Natl Acad Sci USA 91: 1913-1916, 1994.
217. Khanuja PS, Lehr JE, Soule HD, Gehani SK, Noto AC, Choudhury S, Chen R, and Pienta KJ Nuclear matrix proteins in normal and breast cancer cells. Cancer Res 53: 3394-3398 1993.
218. Partin AW, Getzenberg RH, CarMichael MJ, Vindivitch D, Yoo J, Epstein JI and Coffey DS Nuclear matrix protein patterns in human benign prostatic hyperplasia and prostate cancer. Cancer Res 53: 744-746, 1993.
219. Mancini MA, Shan B, Nickerson JA, Penman S, and Lee W-H: The retinoblastoma gene product is a cell cycle-dependent, nuclear matrix associated protein. Proc Natl Acad Sc USA 91: 418-422, 1994.
220. Sperry AO, Blasqez VC, and Garrard WT: Dysfunction of chromosomal loop attachment sites illegitimate recombination linked to matrix association regions and topoisomerase II Proc Natl Acad Sci 86: 5497-5501, 1989.
221. Betz AG, Milstein C, González-Fernández A, Pannell R, Larson T, and Neuberger MS: Elements regulating somatic hypermutation of an immunoglobulin k gene: critical role for the intron enhancer/matrix attachment region. Cell 77: 239-248, 1994.
222. Hartley-Asp B and Kruse E: Nuclear protein matrix as a target for estramustine-induced cell death. Prostate 9: 387-394, 1986.
223. Pienta KJ and Lehr JE: Inhibition of prostate cancer growth by estramustine and etoposide: evidence for interaction at the nuclear matrix. J Urol 149: 482A, 1993.
224. Milner AE, Gordon DJ, Turner BM, and Vaughan ATM: A correlation between DNA-nuclear matrix binding and relative radiosensitivity in two human squamous cell carcinoma cell lines. Int J Radial Res 63: 13-20, 1993.
225. Swaneck GE and Fishman J: Covalent binding of the endogenous estrogen 16α-hydroxyestrone to estradiol receptor in human breast cancer cells: characterization and intranuclear localization. Proc Natl Acad Sci USA 85: 7831-7835, 1988.
226. Boulikas T: Chromatin and nuclear matrix in development and in carcinogenesis: A theory. Int J Oncol 1: 357-372, 1992.
227. Trojan J, Johnson TR, Rudin SD, Ilan J, Tykocinski ML, and Ilan J: Treatment and prevention of rat gliohlastoma by immunogenic C6 cells expressing antisensc insulin-like growth factor I RNA. Science 259: 94-97, 1993.
228. Murakami YS, Brothman AR. Leach RJ, and White RL: Suppression of malignant phenotype in a human prostate cancer cell line by fragments of normal chromosomal region 17q. Cancer Res 55: 3389-3394, 1995.
229. Nakamoto T, Chang CS, Li AK and Chodak GW: Basic fibroblast growth factor in human prostate cancer cells. Cancer Res 52: 571-577, 1992.
230. Sanda MG, Ayyagari SR, Jaffee EM, Epstein JI, Clift SL, Cohen LK, Dranoff G, Pardoll DM, Mulligan RC, and Simons JW: Demonstration of a rational strategy for human prostate cancer gene therapy. J Urol 151: 622-628, 1994.
231. Moody DB, Robinson JC, Ewing CM, Lazenby AJ, and Isaacs WB: Interleukin-2 transfected prostate cancer cells generate a local antitumor effect in vivo. Prostate 24: 244-251, 1994.
232. Vieweg J, Boczkowski D, Roberson KM, Edwards DW, Philip M, Philip R, Rudoll T, Smith C, Robertson C, and Gilboa E: Efficient gene transfer with adeno-associated virus-based plasmids complexed to cationic liposomes for gene therapy of human prostate cancer. Cancer Res 55: 2366-2372, 1995.
233. Redding TW and Shally AV: Investigation of the combination of the agonist D-Trp-6-LHRH and the anti-androgen flutamide in the treatment of Dunning R3327H prostate cancer model. Prostate 6: 219-232, 1985.
234. Sher HI: Prostate cancer: improving the therapeutic index. Semin Oncol 21: 688-693, 1994.
235. Bunone G, Briand P-A, Miksicek RJ, and Picard D: Activation of the unliganded estrogen receptor by EGF involves the MAP kinase pathway and direct phosphorylation. EMBO J 15: 2174-2183, 1996.
236. Crawford D, Eisenberger MA, McLeod DO, Spaulding JT, Benson R, Dorr FA, Blumenstein BA, Davis MA, and Goodman PI: A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med 313: 419-424, 1989.
237. Man J, Sabbatini P, Perez D, Rao L, Modha D, and White E: The E1B 19K protein blocks apoptosis by interacting with and inhibiting the p53-inducible and death-promoting Bax protein. Genes Dev 10: 461-477, 1996.